about
Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational researchHarnessing the antitumor potential of macrophages for cancer immunotherapyMechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy.A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner.The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cellsADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.Programming a Human Commensal Bacterium, Bacteroides thetaiotaomicron, to Sense and Respond to Stimuli in the Murine Gut MicrobiotaListeria monocytogenes: a promising vehicle for neonatal vaccination.Poly-functional and long-lasting anticancer immune response elicited by a safe attenuated Pseudomonas aeruginosa vector for antigens delivery.Comparison of widely used Listeria monocytogenes strains EGD, 10403S, and EGD-e highlights genomic variations underlying differences in pathogenicity.Listeria monocytogenes induces host DNA damage and delays the host cell cycle to promote infection.Live-attenuated bacteria as a cancer vaccine vector.A trip in the "New Microbiology" with the bacterial pathogen Listeria monocytogenes.Recent progress in vaccination against human papillomavirus-mediated cervical cancer.Prospects and progress of Listeria-based cancer vaccines.The Human Vaccines Project: A roadmap for cancer vaccine development.Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations.Trial Watch: DNA vaccines for cancer therapy.Carboxyl-Terminal Residues N478 and V479 Required for the Cytolytic Activity of Listeriolysin O Play a Critical Role in Listeria monocytogenes Pathogenicity.Listeria Monocytogenes: A Model Pathogen Continues to Refine Our Knowledge of the CD8 T Cell Response.
P2860
Q26744094-6B8A00E9-BC8B-4C71-BFD6-F071CA8DFCF4Q26828883-09A380D5-E625-4A31-9786-E4B67DF01EA5Q33755840-DA74A1B8-03BC-417A-BE24-6709098D5011Q33849628-214A8462-A042-4239-95DE-79ED1A714800Q35832233-173CBD46-DC6A-4242-8EBE-1589070AFBFBQ35886730-309A9FB6-EFE3-4AEB-BE1F-0FE6ED89F5F2Q36602759-F726E876-DC7C-4DDF-A0CB-E96F66A78379Q36977730-82C5098A-7139-468B-9E78-80E0E22E90ABQ37502444-718AE1CE-93CF-4306-98AC-346267E2665BQ37687817-F3FA391C-1289-4D86-B076-F9D7389DE0FCQ37698900-A4706BE5-41F4-49D3-8CCD-764ED0C5FB11Q38152473-641BF182-BD1E-412D-B803-764953A60955Q38218723-6CA51476-AF5B-43BD-B7F6-C8E322C2A8F0Q38370782-769FB6CB-02A4-4B1D-BAFF-0A688AAD52B2Q38617306-2341ABAB-C8BC-4626-AF00-E81E16E55A36Q38807692-5E3D2E85-C98C-4BDF-8F2B-F27AC46A0B13Q40084604-D5103B3E-885E-41D1-982F-CFF6DF9229AAQ42552005-9153E9D6-1FFD-4F46-BB86-4FF6A47975E9Q47105902-A7730D95-FCFC-4DAE-B8F3-1D219BFF5EACQ55645457-87A8920F-4393-4CD9-B4CC-E6CED10B2623
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Live-attenuated Listeria-based immunotherapy.
@en
type
label
Live-attenuated Listeria-based immunotherapy.
@en
prefLabel
Live-attenuated Listeria-based immunotherapy.
@en
P2860
P356
P1476
Live-attenuated Listeria-based immunotherapy
@en
P2093
John Rothman
P2860
P304
P356
10.1586/ERV.13.34
P577
2013-05-01T00:00:00Z